In an emulated target trial, a single dose of modified vaccinia Ankara-Bavarian Nordic vaccine was moderately effective in ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities.

Contract will further strengthen the U.S, bulk vaccine inventory and secure additional freeze-dried doses <li /> Deliveries planned for ...

In a recent study, one dose of modified vaccinia Ankara-Bavarian Nordic vaccine had estimated vaccine effectiveness of 58%. HealthDay News — One dose of modified vaccinia Ankara-Bavarian Nordic ...

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA Represents the second EMA approval of an MVA-BN-based vaccine for a younger ...

Lessons learned from the COVID pandemic have left the world in a much better position to tackle the current mpox epidemic ...

Mpox ( formerly known as monkeypox) is a viral infection that can be prevented with just a single dose of an existing vaccine ...

On September 13, 2024, the World Health Organization (WHO) announced that it added the first vaccine against monkeypox (mpox) to its ...

The African health agency says that Rwanda has started a vaccination campaign against mpox with 1,000 doses it obtained from ...

MVA-BN is approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA. This is the second EMA approval of an MVA-BN-based vaccine for a younger ...